Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease

Trial Profile

Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Nifurtimox (Primary)
  • Indications Chagas disease
  • Focus Therapeutic Use
  • Acronyms CHICO
  • Sponsors Bayer
  • Most Recent Events

    • 10 Jul 2017 Planned End Date changed from 30 Nov 2018 to 31 Jul 2018.
    • 10 Jul 2017 Planned primary completion date changed from 30 Nov 2018 to 31 Jul 2018.
    • 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top